Skip to content
How It Works
Explore
Resources Ask a Question
Who It's For
Patients Caregivers Providers
Log In Ask a Question
PubMed This is a summary of 18 peer-reviewed journal articles Updated
Hematology

Building Your Expert Care Team and Preparing for Your First Visit

At a Glance

For a rare cancer like BPDCN, patients should seek care at a specialized center with a multidisciplinary team including a hematologist-oncologist, dermatologist, and stem cell transplant expert. Always bring physical biopsy slides, flow cytometry reports, and imaging discs to your first visit.

Because Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) is so rare, your care team should look different than it would for a common cancer. You are not just looking for an oncologist; you are building a highly specialized “squad” of experts who understand the nuances of this specific disease [1][2].

Your Multidisciplinary Team

A “gold standard” care team for BPDCN should ideally include the following specialists, often found at NCI-designated or academic cancer centers [1]:

  • Hematologist-Oncologist: A blood cancer specialist, ideally one who focuses on rare myeloid malignancies or leukemias [3].
  • Dermatologist: Since BPDCN often involves the skin, a dermatologist helps monitor skin response to treatment and can perform follow-up biopsies [4][5].
  • Stem Cell Transplant Specialist: Because an allogeneic transplant is often the goal for long-term remission, this doctor should be involved from day one [6][7].
  • Hematopathologist: This is the “doctor’s doctor” who looks at your cells under a microscope. Expertise in BPDCN is vital to ensure your markers (like CD123, CD4, and CD56) are interpreted correctly [8][9].
  • Specialized Nursing Staff: Nurses experienced with tagraxofusp are essential for monitoring the specific side effects of this targeted therapy, such as weight gain or swelling [10][11].

The “Survival Kit”: Records You Must Bring

When you go for a second opinion or to a specialized center, “reports” are not enough. The specialists there will want to see the actual tissue to confirm the diagnosis themselves [12][13]. You should request the following from your original diagnosing hospital:

  1. Pathology Materials: Ask for the physical paraffin-embedded tissue blocks from your skin and bone marrow biopsies. If they cannot give blocks, ask for at least 10-15 unstained slides [12][13].
  2. Flow Cytometry Reports: These reports show the specific proteins (markers) found on the surface of your cancer cells [8].
  3. Molecular/Genetic Testing (NGS): Results showing mutations like TET2, ASXL1, or ZRSR2 [14][15].
  4. Imaging: A disc containing the actual images (not just the written report) of any PET scans or CT scans [16].

Evaluating a Potential Care Team

Rare diseases require rare expertise. Don’t be afraid to “interview” your potential doctors. A center with high BPDCN volume is better equipped to handle the complexities of the disease and its treatments [2][3].

What to Look For Why It Matters
NCI-Designated Center These centers often have more experience with rare cancers and better access to clinical trials [17].
BPDCN Volume Experience with just 5-10 cases makes a center significantly more expert than most community hospitals [2].
CLS Protocol The center should have a clear, written protocol for managing Capillary Leak Syndrome, the most serious side effect of tagraxofusp [10][18].

By arriving with the right records and asking the right questions, you shift from being a “passive patient” to an “active partner” in your care, ensuring your team has the expertise needed to manage this aggressive disease [1][6].

Common questions in this guide

What types of doctors should be on my BPDCN care team?
Your BPDCN care team should ideally include a hematologist-oncologist specializing in rare leukemias, a dermatologist, a stem cell transplant specialist, and an expert hematopathologist. Specialized nursing staff are also critical for managing specific treatments.
What medical records do I need to bring to my first appointment?
You should bring your physical tissue blocks or unstained slides from your biopsies, flow cytometry reports, molecular testing results, and the actual imaging discs from your PET or CT scans. These materials allow your new specialists to independently confirm your rare diagnosis.
Why is it important to go to a specialized center for BPDCN?
Because BPDCN is extremely rare, treatments require highly specialized management protocols. Centers that treat even a small number of cases have significantly more expertise in managing the disease and severe side effects like capillary leak syndrome compared to standard hospitals.
Should a stem cell transplant doctor be involved right away?
Yes, a stem cell transplant specialist should ideally be involved from day one. Because an allogeneic stem cell transplant is often the ultimate goal for achieving long-term remission, early consultation and planning are essential.

Questions to Ask Your Doctor

Curated prompts to bring to your next appointment.

  1. 1.How many BPDCN cases has this center treated, and specifically, how many patients have received tagraxofusp here?
  2. 2.Does this center have a multidisciplinary tumor board that will review my case specifically for BPDCN?
  3. 3.Do you have a specialized protocol for monitoring and managing Capillary Leak Syndrome (CLS)?
  4. 4.Is there a stem cell transplant physician on my core care team starting now?
  5. 5.Will you be re-reviewing my pathology slides and blocks in-house to confirm the BPDCN diagnosis?

Questions For You

Tap a prompt to share your answer — we'll use it plus this page's context to start a tailored conversation.

References

References (18)
  1. 1

    Cutaneous Manifestation of a Rare Haematological Malignancy: A Case Report of the Presentation, Diagnosis, and Management of Blastic Plasmacytoid Dendritic Cell Neoplasm.

    Hassan SL, Chatha DE

    Cureus 2025; (17(7)):e87604 doi:10.7759/cureus.87604.

    PMID: 40786289
  2. 2

    Real-world management of blastic plasmacytoid dendritic cell neoplasm at an academic center with a broad regional referral base.

    Krah NM, Hoeg R, Shami PJ, et al.

    Leukemia research reports 2025; (24()):100541 doi:10.1016/j.lrr.2025.100541.

    PMID: 40917153
  3. 3

    Treatment of patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN): focus on the use of tagraxofusp and clinical considerations.

    Pemmaraju N, Madanat YF, Rizzieri D, et al.

    Leukemia & lymphoma 2024; (65(5)):548-559 doi:10.1080/10428194.2024.2305288.

    PMID: 38391126
  4. 4

    BLASTIC PLASMACYTOID DENDRITIC CELL NEOPLASM --A RAPIDLY EVOLVING ENTITY. CASE REPORT.

    Andrese E, Solovăstru LG, Dimofte G, et al.

    Revista medico-chirurgicala a Societatii de Medici si Naturalisti din Iasi 2015; (119(2)):379-83.

    PMID: 26204640
  5. 5

    Unusual Nodule on the Left Leg of an Elderly Woman-A Case Report: Challenge.

    Cazzato G, Ingravallo G, Vitiello P, et al.

    The American Journal of dermatopathology 2025; (47(6)):e64-e66 doi:10.1097/DAD.0000000000002961.

    PMID: 40172049
  6. 6

    Tagraxofusp as treatment for patients with blastic plasmacytoid dendritic cell neoplasm.

    Lee SS, McCue D, Pemmaraju N

    Expert review of anticancer therapy 2020; (20(7)):543-550 doi:10.1080/14737140.2020.1776120.

    PMID: 32460559
  7. 7

    A misdiagnosed case of blastic plasmacytoid dendritic cell neoplasm experiencing multiple recurrences who underwent allogeneic stem cell transplantation: a case report.

    Salemi F, Mortazavizadeh SMR, Mirmoeeni S, et al.

    Journal of medical case reports 2021; (15(1)):292 doi:10.1186/s13256-021-02860-z.

    PMID: 34022952
  8. 8

    Comparison and Development of Immunohistochemical Diagnostic Criteria for Blastic Plasmacytoid Dendritic Cell Neoplasm.

    Sakamoto K, Baba S, Okumura Y, et al.

    Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc 2023; (36(10)):100253 doi:10.1016/j.modpat.2023.100253.

    PMID: 37380058
  9. 9

    Top Ten Lymphoproliferative Lesions Not to Miss When Evaluating Oral Ulcer Biopsies.

    Hyrcza MD, Lindenmuth TR, Auerbach A

    Head and neck pathology 2023; (17(1)):99-118 doi:10.1007/s12105-023-01532-2.

    PMID: 36928739
  10. 10

    Targeting CD123 in BPDCN: an emerging field.

    DiPippo AJ, Wilson NR, Pemmaraju N

    Expert review of hematology 2021; (14(11)):993-1004 doi:10.1080/17474086.2021.1988848.

    PMID: 34607517
  11. 11

    Recent developments in the treatment of blastic plasmacytoid dendritic cell neoplasm.

    Economides MP, Konopleva M, Pemmaraju N

    Therapeutic advances in hematology 2019; (10()):2040620719874733 doi:10.1177/2040620719874733.

    PMID: 31579499
  12. 12

    Blastic Plasmacytoid Dendritic Cell Neoplasm; A Report of Three Cases.

    Safaei A, Monabati A, Mokhtari M, et al.

    Iranian journal of medical sciences 2019; (44(1)):74-78.

    PMID: 30666080
  13. 13

    Diagnostic approach to blastic plasmacytoid dendritic cell neoplasm: historical perspectives and current understanding.

    Sakamoto K, Takeuchi K

    Journal of clinical and experimental hematopathology : JCEH 2025; (65(1)):1-16 doi:10.3960/jslrt.24069.

    PMID: 40159280
  14. 14

    Germline missense NF1 mutation in an elderly patient with a blastic plasmacytoid dendritic cell neoplasm.

    Szczepaniak A, Machnicki M, Gniot M, et al.

    International journal of hematology 2019; (110(1)):102-106 doi:10.1007/s12185-019-02642-w.

    PMID: 30977107
  15. 15

    Localized blastic plasmacytoid dendritic cell neoplasm associated with progressive clonal hematopoiesis and myelodysplastic syndrome.

    Julin C, Nielsen SL, Grantzau TL, et al.

    APMIS : acta pathologica, microbiologica, et immunologica Scandinavica 2025; (133(1)):e13486 doi:10.1111/apm.13486.

    PMID: 39465574
  16. 16

    Characteristics and outcomes of patients with blastic plasmacytoid dendritic cell neoplasm treated with frontline HCVAD.

    Pemmaraju N, Wilson NR, Garcia-Manero G, et al.

    Blood advances 2022; (6(10)):3027-3035 doi:10.1182/bloodadvances.2021006645.

    PMID: 35061885
  17. 17

    The role of targeted therapies in blastic plasmacytoid dendritic cell neoplasm.

    Azevedo RS, Nooruddin Z, Bhatia S, et al.

    Expert opinion on biological therapy 2026; (26(1)):15-24 doi:10.1080/14712598.2025.2610291.

    PMID: 41447337
  18. 18

    Tagraxofusp for the Treatment of Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN): A Brief Report on Emerging Data.

    Beziat G, Ysebaert L

    OncoTargets and therapy 2020; (13()):5199-5205 doi:10.2147/OTT.S228342.

    PMID: 32606740

This page provides educational information on building a BPDCN care team and preparing for medical visits. It is not a substitute for professional medical advice, diagnosis, or treatment planning.

Get notified when new evidence is published on Blastic plasmacytoid dendritic cell neoplasm.

We monitor PubMed for new peer-reviewed studies on this topic and email a short summary when something meaningful changes.